Literature DB >> 33867705

Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.

Nafija Serdarevic1, Pradeep Dabla2, Adina Elena Stanciu3.   

Abstract

Recent studies have shown that there are systematic differences among total and free prostate-specificantigen (PSA) immunoassays. In this study we analyzedintermethod differences in total PSA (tPSA) and free PSA(fPSA) measurement using ARCHITECT i2000SR (Abbott Diagnostics) and COBAS E601 (Roche Diagnostics). A number of 160 blood samples were tested for tPSA and 50 samples for fPSA (selecting only sampleswith tPSA: 4.1-10.0 μg/L). Passing-Bablok regression analysis was used to compare the two analytical methods fortPSA, fPSA and percentage of fPSA (%fPSA). A strong correlation was noticed between ARCHITECT i2000SR and COBAS E601 for tPSA, fPSA and %fPSA (r between 0.94 and 0.99). Concentrations of tPSA and fPSA measured by COBAS E601 were higher thanthose measured by ARCHITECT i2000SR with a bias of 0.8 μg/L for tPSA and 0.14 μg/L for fPSA. Analyzing therelative difference between methods for fPSA and %fPSA, COBAS E601 exceed a 10% relative difference limit. Our study confirms that there are differences in measured concentrations of tPSA and fPSA byvarious commercial methods. Because clinical judgment on subsequent diagnostic procedures, such as prostatebiopsy, is based on tPSA and fPSA results, tests harmonization should be a priority. © Association of Clinical Biochemists of India 2019.

Entities:  

Keywords:  Free PSA; Immunoassay; Method comparison; Quality control; Total PSA

Year:  2019        PMID: 33867705      PMCID: PMC7994458          DOI: 10.1007/s12291-019-0818-6

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  26 in total

1.  Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England.

Authors:  Andrew W Roddam; Janet Rimmer; Claire Nickerson; Anthony Milford Ward
Journal:  Ann Clin Biochem       Date:  2006-01       Impact factor: 2.057

Review 2.  Why do immunoassays for tumour markers give differing results?--a view from the UK National External Quality Assessment Schemes.

Authors:  C M Sturgeon; J Seth
Journal:  Eur J Clin Chem Clin Biochem       Date:  1996-09

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

Review 4.  Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy.

Authors:  Jacek Koziorowski; Adina E Stanciu; Vanessa Gomez-Vallejo; Jordi Llop
Journal:  Anticancer Agents Med Chem       Date:  2017       Impact factor: 2.505

5.  Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.

Authors:  Stacy Loeb
Journal:  BJU Int       Date:  2015-04       Impact factor: 5.588

6.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.

Authors:  Marion A Gray; Russell R Cooke; Philip Weinstein; John N Nacey
Journal:  Ann Clin Biochem       Date:  2004-05       Impact factor: 2.057

8.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

Authors:  Catharine M Sturgeon; Michael J Duffy; Ulf-Håkan Stenman; Hans Lilja; Nils Brünner; Daniel W Chan; Richard Babaian; Robert C Bast; Barry Dowell; Francisco J Esteva; Caj Haglund; Nadia Harbeck; Daniel F Hayes; Mads Holten-Andersen; George G Klee; Rolf Lamerz; Leendert H Looijenga; Rafael Molina; Hans Jørgen Nielsen; Harry Rittenhouse; Axel Semjonow; Ie-Ming Shih; Paul Sibley; György Sölétormos; Carsten Stephan; Lori Sokoll; Barry R Hoffman; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2008-12       Impact factor: 8.327

9.  Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.

Authors:  Xavier Filella; Joan Alcover; Rafael Molina; Pilar Luque; Juan M Corral; Josep M Augé; Francisca Coca
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

10.  Prostate specific antigen for early detection of prostate cancer: longitudinal study.

Authors:  Benny Holmström; Mattias Johansson; Anders Bergh; Ulf-Håkan Stenman; Göran Hallmans; Pär Stattin
Journal:  BMJ       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.